Industry
Biotechnology
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
Loading...
Open
0.78
Mkt cap
27M
Volume
67K
High
0.80
P/E Ratio
-3.32
52-wk high
3.25
Low
0.75
Div yield
N/A
52-wk low
0.45
Portfolio Pulse from
November 06, 2024 | 4:30 pm
Portfolio Pulse from Benzinga Newsdesk
November 01, 2024 | 10:55 am
Portfolio Pulse from Benzinga Newsdesk
October 31, 2024 | 1:03 pm
Portfolio Pulse from Benzinga Insights
October 31, 2024 | 12:10 pm
Portfolio Pulse from Benzinga Insights
October 31, 2024 | 12:09 pm
Portfolio Pulse from Benzinga Newsdesk
October 31, 2024 | 11:45 am
Portfolio Pulse from Avi Kapoor
October 31, 2024 | 10:52 am
Portfolio Pulse from Benzinga Newsdesk
October 24, 2024 | 8:25 pm
Portfolio Pulse from Benzinga Newsdesk
October 07, 2024 | 12:04 pm
Portfolio Pulse from Benzinga Newsdesk
August 19, 2024 | 11:11 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.